Table 1 Baseline characteristics of all 62 participants
Overall (N = 62) | Galcanezumab (N = 31) | OMPM (N = 31) | P | |
|---|---|---|---|---|
Age (years) | 36.5 (29.0–48.0) | 35.5 (28.8–50.4) | 37.2 (29.0–45.7) | 0.87 |
Sex | 0.74 | |||
Female | 51 (82%) | 26 (84%) | 25 (81%) | |
Male | 11 (18%) | 5 (16%) | 6 (19%) | |
Comorbidities | ||||
Depression | 14 (23%) | 7 (23%) | 7 (23%) | > 0.99 |
Anxiety | 9 (15%) | 4 (13%) | 5 (16%) | > 0.99 |
Myofascial pain syndrome | 24 (39%) | 12 (39%) | 12 (39%) | > 0.99 |
Fibromyalgia | 3 (5%) | 2 (6%) | 1 (3%) | > 0.99 |
Obstructive sleep apnea | 2 (3%) | 0 (0%) | 2 (6%) | 0.49 |
Headache frequency per month | 12.5 (10.0–21.0) | 12.0 (8.0–21.0) | 15.0 (10.0–22.0) | 0.32 |
MIDAS | 27.5 (13.0–60.0) | 30.0 (14.0–79.0) | 25.0 (13.0–50.0) | 0.30 |
Acute medications at baseline | ||||
Acetaminophen | 16 (25.8%) | 8 (25.8%) | 8 (25.8%) | > 0.99 |
NSAID | 29 (46.8%) | 18 (58.1%) | 11 (35.5%) | 0.08 |
Tramadol | 2 (3.2%) | 1 (3.2%) | 1 (3.2%) | > 0.99 |
Triptan | 14 (22.6%) | 5 (16.1%) | 9 (29.0%) | 0.22 |
Ergot | 5 (8.1%) | 3 (9.7%) | 2 (6.5%) | > 0.99 |
Preventive medications at baseline | ||||
Tricyclic antidepressants | 18 (29%) | 7 (23%) | 11 (35%) | 0.26 |
Beta-blockers | 11 (18%) | 4 (13%) | 7 (23%) | 0.32 |
Antiseizure medications | 9 (15%) | 6 (19%) | 3 (10%) | 0.47 |
Calcium-channel blocker | 4 (6.5%) | 0 (0%) | 4 (12.9%) | 0.11 |
Migraine Class | > 0.99 | |||
HFEM | 29 (47%) | 14 (45%) | 15 (48%) | |
CM | 33 (53%) | 17 (55%) | 16 (52%) |